GSTT1 as a Prognosticator for Recurrence and Progression in Patients with Non-Muscle-Invasive Bladder Cancer

Although polymorphisms in glutathione S-transferase (GST) have been associated with the risk of bladder cancer (BC), few reports provide information about the development of BC. The aim of the present study was to investigate the effect of homozygous glutathione S-transferase-μ (GSTM1) and glutathione S-transferase-&phis; (GSTT1) deletions as prognostic markers in non-muscle-invasive bladder cancer (NMIBC). A total of 241 patients with primary NMIBC were enrolled in this study. GSTM1 and GSTT1 polymorphisms were analyzed by multiplex polymerase chain reaction (PCR) using blood genomic DNA. The results were compared with clinicopathological parameters. The prognostic significance of the GSTs was evaluated by Kaplan-Meier and multivariate Cox regression model. A statistically significant association between genotype and histopathological parameter was not observed. The patients with the GSTT1-positive genotype had significantly reduced recurrence- and progression-free survival than those with the GSTT1-null genotype (log-rank test, p < 0.05, respectively). Recurrenceand progressionfree survival were not related to the GSTM1 genotypes. In multivariate regression analysis, the GSTT1positive genotype was the independent predictor for recurrence [hazard ratio (HR), 1.631; p = 0.043] and progression (HR, 3.418; p = 0.006). These results suggested that the GSTT1 genotype could be a useful prognostic marker for recurrence and progression in NMIBC.

[1]  Wun-Jae Kim,et al.  Environmental factors promoting bladder cancer , 2009, Current opinion in urology.

[2]  S. Chanock,et al.  Genetic variation in SIPA1 in relation to breast cancer risk and survival after breast cancer diagnosis , 2009, International journal of cancer.

[3]  N. Malats,et al.  TGFB1 and TGFBR1 polymorphic variants in relationship to bladder cancer risk and prognosis , 2009, International journal of cancer.

[4]  M. Babjuk,et al.  EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder. , 2008, European urology.

[5]  T. Reckwitz,et al.  The Influence of Polymorphisms of Glutathione S-Transferases M1 and M3 on the Development of Human Urothelial Cancer , 2008, Journal of toxicology and environmental health. Part A.

[6]  P. Schellhammer,et al.  Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update. , 2007, The Journal of urology.

[7]  Leah E. Mechanic,et al.  Lung cancer survival and functional polymorphisms in MBL2, an innate-immunity gene. , 2007, Journal of the National Cancer Institute.

[8]  Wun-Jae Kim,et al.  Biomarkers in Bladder Cancer: Present Status and Perspectives , 2007, Biomarker insights.

[9]  D. Michaud,et al.  Polymorphisms in GSTT1, GSTM1, NAT1 and NAT2 genes and bladder cancer risk in men and women , 2006, BMC Cancer.

[10]  A. Zlotta.  NAT2 Slow Acetylation, GSTM1 Null Genotype, and Risk of Bladder Cancer: Results from the Spanish Bladder Cancer Study and Meta-Analyses , 2006 .

[11]  Wun-Jae Kim,et al.  GSTT1-null genotype is a protective factor against bladder cancer. , 2002, Urology.

[12]  A. Evangelou,et al.  The role of N-acetyltransferase-2 and glutathione S-transferase on the risk and aggressiveness of bladder cancer. , 2002, Anticancer research.

[13]  Henry J. Lin,et al.  Pooled analysis and meta-analysis of glutathione S-transferase M1 and bladder cancer: a HuGE review. , 2002, American journal of epidemiology.

[14]  F. Greene.  The American Joint Committee on Cancer: updating the strategies in cancer staging. , 2002, Bulletin of the American College of Surgeons.

[15]  N. Rothman,et al.  Combined effect of glutathione S-transferase M1 and T1 genotypes on bladder cancer risk. , 2002, Cancer letters.

[16]  R. Houlston,et al.  Glutathione S-transferase μ1 (GSTM1) status and bladder cancer risk : a meta-analysis , 2000 .

[17]  Ho Kim,et al.  Polymorphisms of N-acetyltransferase 2, glutathione S-transferase mu and theta genes as risk factors of bladder cancer in relation to asthma and tuberculosis. , 2000, The Journal of urology.

[18]  R. Strange,et al.  Glutathione S-transferase: genetics and role in toxicology. , 2000, Toxicology letters.

[19]  Y. H. Lee,et al.  The role of bcl-2, p53, and ki-67 index in predicting tumor recurrence for low grade superficial transitional cell bladder carcinoma. , 2000, The Journal of urology.

[20]  T. Kawamoto,et al.  Effects of glutathione S-transferase (GST) M1 and GSTT1 genotypes on urothelial cancer risk. , 1998, Cancer letters.

[21]  J. Brockmöller,et al.  Combined analysis of inherited polymorphisms in arylamine N-acetyltransferase 2, glutathione S-transferases M1 and T1, microsomal epoxide hydrolase, and cytochrome P450 enzymes as modulators of bladder cancer risk. , 1996, Cancer research.

[22]  C. Bloomfield,et al.  Increased risk for myelodysplastic syndromes in individuals with glutathione transferase theta 1 (GSTT1) gene defect , 1996, The Lancet.

[23]  Jack A. Taylor,et al.  Genetic risk and carcinogen exposure: a common inherited defect of the carcinogen-metabolism gene glutathione S-transferase M1 (GSTM1) that increases susceptibility to bladder cancer. , 1993, Journal of the National Cancer Institute.

[24]  A. Miller,et al.  Tobacco use, occupation, coffee, various nutrients, and bladder cancer. , 1980, Journal of the National Cancer Institute.

[25]  Li-Rong Zhang,et al.  Association of NAT2, GSTM1, GSTT1, CYP2A6, and CYP2A13 gene polymorphisms with susceptibility and clinicopathologic characteristics of bladder cancer in Central China. , 2009, Cancer detection and prevention.

[26]  D. Michaud,et al.  Polymorphisms in GSTT1, GSTM1, NAT1 and NAT2 genes and bladder cancer risk in men and women , 2006, BMC Cancer.

[27]  Wun-Jae Kim,et al.  Genotypes of TNF-alpha, VEGF, hOGG1, GSTM1, and GSTT1: useful determinants for clinical outcome of bladder cancer. , 2005, Urology.

[28]  R. Houlston,et al.  Glutathione S-transferase mu1 (GSTM1) status and bladder cancer risk: a meta-analysis. , 2000, Mutagenesis.

[29]  E. Biros,et al.  The role of human glutathione S-transferases M1 and T1 in individual susceptibility to bladder cancer. , 1999, Physiological research.

[30]  H. Ozen.  Bladder cancer. , 1998, Current opinion in oncology.

[31]  T. Reckwitz,et al.  Glutathione S-transferase GSTM1 and GSTT1 null genotypes as potential risk factors for urothelial cancer of the bladder , 1996, Archives of Toxicology.